OTLK logo

OUTLOOK THERAPEUTICS INC

OTLKNASDAQ
🏆 #3827 by market capEarnings Dec 17 · PostUS Equity
$0.54▲ $0.01 (+1.16%)
Pre-market · at close
🔔
Track OTLK
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.2%
7d▼ 4.8%
14d▲ 8.1%
30d▼ 13.8%
ytd▼ 65.8%
1y▼ 58.2%
🏦Market Cap
$131M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.52 – $0.55
52-Week Range
$0.16 – $2.54
Volume (shares)
19,646
Avg Volume (shares)
—
Shares Outstanding
243.4M
Next Earnings
2026-12-17

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$9,000
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.87
Dividend Yield
—
Dilution (1yr)
+148.4%
OTLK logo

OUTLOOK THERAPEUTICS INC

OTLK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$67M▼ −6.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$52M▼ −24.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
60.2M▲ +148.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$28M▼ −$3M YoY
StockOtter · stockotter.space

About OUTLOOK THERAPEUTICS INC

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.